The Division of Microbiology and Infectious Diseases (DMID) supports research and provides resources for all stages of product development, partnering with public and private institutions to move advances through the product development pipeline. The results are research discoveries that are transforming the prevention, diagnosis, and treatment of infectious diseases. These scientific success showcase highlights just a few of these achievements.
New Anthrax Vaccine with Faster Protection
August 15, 2023The U.S. Food and Drug Administration (FDA) licensed CYFENDUS™, a novel anthrax vaccine developed with extensive support from NIAID and federal collaborators. Also known as AV7909 the two-dose vaccine offers faster protection than the previously approved three-dose anthrax vaccine, BioThrax. The licensure is an important step by the U.S. Government to prepare for intentional or naturally…
The First Approved Treatment for COVID-19
December 13, 2024After the emergence of SARS-CoV-2, NIAID efforts played a critical role in accelerating the development of new therapeutics and other countermeasures. In January 2020, the first cases of COVID-19 were reported in the United States. One month later, the Adaptive COVID-19 Treatment Trial (ACTT) began. Sponsored by NIAID, this was one of the first clinical trials for an experimental COVID-19…
Point-of-Care Diagnostics for Common Sexually Transmitted Infections
December 18, 2024NIAID supported a clinical study of the Visby Medical Sexual Health Test, a palm-sized, rapid point-of-care diagnostic that can detect trichomoniasis, chlamydia, and gonorrhea infections in women using a self-collected vaginal swab. The highly sensitive, nucleic acid amplification-based PCR diagnostic returns results in less than 30 minutes, allowing patients to receive an accurate diagnosis…
